THE NovaSure RFC10 Controller
Enhanced RFC10 controller for improved workflow

Working closely with customers, Hologic engineers have incorporated several physician-inspired and patient-focused enhancements to the NovaSure RFC10 controller. Here’s how these intuitive graphics help to improve workflow.

workflow
1
Touchscreen Interface
The responsiveness of our advanced touchscreen interface is set to react to user input.
screen
2
Ablation Timer and Summary Screen
The ablation time and summary screen displays cumulative running ablation time and total ablation time at the end of the procedure. Length, width and power level are also displayed. The prior procedure data is also recoverable if the controller is powered off and on.
instructions
3
Procedural Instructions On Interface
When you encounter an error message, use the IFU procedural instructions displayed on the interface to walk through corrective actions.
alarms
4
Volume-Controlled and Mutable Alarms
Turn the alarms down—or mute them altogether—so that patients aren’t startled during the procedure. This is a great feature when performing the procedure in outpatients.

Now that I’ve had the NovaSure
procedure
, I have a new life!

Janelle Shaw, NovaSure Patient
References
  1. Hologic, Inc. Data on file; 2004-2018. Based on units shipped from 2004-2018.
IMPORTANT SAFETY INFORMATION

NovaSure® endometrial ablation is for premenopausal women with heavy periods due to benign causes who are finished childbearing. Pregnancy following the NovaSure procedure can be dangerous. The NovaSure procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. NovaSure endometrial ablation is not a sterilisation procedure. Rare but serious risks include, but are not limited to, thermal injury, perforation and infection. Temporary side effects may include cramping, nausea, vomiting, discharge and spotting. Inform patients to contact you if they experience a possible side effect related to use of this product. For detailed benefit and risk information, please consult the IFU.